Multiple myeloma, the second most common haematological malignancy worldwide after non-Hodgkin lymphoma, is characterized by the abnormal proliferation of plasma cells in the bone marrow. The malignant plasma cells replace normal blood cells, which can lead to anaemia, bone marrow failure and renal damage.

The authors declare no competing interests.